Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2018
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Anterior uveitis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms C-VIEW
- Sponsors UCB Biopharma
- 19 Feb 2018 Planned End Date changed from 1 Apr 2020 to 1 Mar 2020.
- 19 Feb 2018 Planned primary completion date changed from 1 Feb 2020 to 1 Jan 2020.
- 05 Feb 2018 Status changed from recruiting to active, no longer recruiting.